Clinical Trials Register

Summary
EudraCT Number:	2017-002383-40
Sponsor's Protocol Code Number:	ICC_APL_Study_02
National Competent Authority:	Czechia - SUKL
Clinical Trial Type:	EEA CTA
Trial Status:	Ongoing
Date on which this record was first entered in the EudraCT database:	2021-08-31
Trial results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Czechia - SUKL

A.2

EudraCT number

2017-002383-40

A.3

Full title of the trial

Treatment study for children and adolescents with Acute Promyelocytic Leukemia

Studie pro léčbu dětí a dospívajících s akutní promyelocytární leukémií

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

Treatment study for children and adolescents with Acute Promyelocytic Leukemia

Studie pro léčbu dětí a dospívajících s akutní promyelocytární leukémií

A.3.2

Name or abbreviated title of the trial where available

ICC APL Study 02

A.4.1

Sponsor's protocol code number

ICC_APL_Study_02

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica
B.1.3.4	Country	Italy
B.3.1 and B.3.2	Status of the sponsor	Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	AIEOP
B.4.2	Country	Italy
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	AIEOP
B.5.2	Functional name of contact point	Centro Operativo
B.5.3	Address:
B.5.3.1	Street Address	Via Massarenti 11
B.5.3.2	Town/ city	Bologna
B.5.3.3	Post code	40138
B.5.3.4	Country	Italy
B.5.4	Telephone number	+390512144667
B.5.5	Fax number	+39051345759
B.5.6	E-mail	studiclinici@aieop.org

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.2	Country which granted the Marketing Authorisation	Italy
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Citarabina
D.3.4	Pharmaceutical form	Concentrate for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intrathecal use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Citarabina
D.3.9.1	CAS number	147-94-4
D.3.9.2	Current sponsor code	IMP1
D.3.9.3	Other descriptive name	CYTARABINE
D.3.9.4	EV Substance Code	SUB06880MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	up to
D.3.10.3	Concentration number	20
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.2	Country which granted the Marketing Authorisation	Italy
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Tretinoina
D.3.4	Pharmaceutical form	Capsule
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Tretinoina
D.3.9.1	CAS number	302-79-4
D.3.9.2	Current sponsor code	IMP2
D.3.9.3	Other descriptive name	TRETINOIN
D.3.9.4	EV Substance Code	SUB11246MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	up to
D.3.10.3	Concentration number	10
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 3
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.2	Country which granted the Marketing Authorisation	Italy
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Metotrexato
D.3.4	Pharmaceutical form	Powder for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intrathecal use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Metotrexato
D.3.9.1	CAS number	59-05-2
D.3.9.2	Current sponsor code	IMP3
D.3.9.3	Other descriptive name	METHOTREXATE
D.3.9.4	EV Substance Code	SUB08856MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	up to
D.3.10.3	Concentration number	25
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 4
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.2	Country which granted the Marketing Authorisation	Italy
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Triossido di arsenico
D.3.4	Pharmaceutical form	Powder for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Triossido di arsenico
D.3.9.1	CAS number	1327-53-3
D.3.9.2	Current sponsor code	IMP4
D.3.9.3	Other descriptive name	ARSENIC TRIOXIDE
D.3.9.4	EV Substance Code	SUB12467MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg/l milligram(s)/litre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	1
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 5
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	Mylotarg
D.2.1.1.2	Name of the Marketing Authorisation holder	Pfizer Ltd
D.2.1.2	Country which granted the Marketing Authorisation	Italy
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	Yes
D.2.5.1	Orphan drug designation number	EU/3/00/005-EMEA/OD/022/00
D.3 Description of the IMP
D.3.4	Pharmaceutical form	Powder for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	GEMTUZUMAB OZOGAMICIN
D.3.9.1	CAS number	220578-59-6
D.3.9.3	Other descriptive name	Gentuzumab ozogamicin
D.3.9.4	EV Substance Code	SUB20794
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	5
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	No
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	Yes
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	Yes
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 6
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.2	Country which granted the Marketing Authorisation	Italy
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Metilprednisolone
D.3.4	Pharmaceutical form	Concentrate for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intrathecal use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Metilprednisolone
D.3.9.1	CAS number	83-43-2
D.3.9.3	Other descriptive name	METHYLPREDNISOLONE
D.3.9.4	EV Substance Code	SUB08872MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	up to
D.3.10.3	Concentration number	40
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

acute promyelocytic leukemia (APL) in children and adolescents

akutní promyelocytární leukémie u dětí a dospívajících

E.1.1.1

Medical condition in easily understood language

acute promyelocytic leukemia (APL) in children and adolescents

akutní promyelocytární leukémie u dětí a dospívajících

E.1.1.2

Therapeutic area

Diseases [C] - Cancer [C04]

MedDRA Classification

E.1.3

Condition being studied is a rare disease

Yes

E.2 Objective of the trial

E.2.1

Main objective of the trial

• To assess, in an international pediatric study, the efficacy, in terms of event-free survival, of a combination of ATO and ATRA in newly diagnosed SR APL children and adolescents and to explore the safety and efficacy of a combination therapy comprising ATRA/ATO + GO in HR APL.

Hlavním cílem této studie je zhodnotit bezpečnost a účinnost léčby, která kombinuje oxid arsenitý (ATO) a kyselinu all-trans retinovou (ATRA), pokud jde o přežití bez návratu onemocnění u pacientů s nově diagnostikovanou standardně rizikovou akutní promyelocytární leukémií a zhodnotit bezpečnost a účinnost léčby, která kombinuje oxid arsenitý (ATO), kyselinu all-trans retinovou (ATRA) a gemtuzumab ozogamicin (GO), pokud jde o přežití bez návratu onemocnění u pacientů s nově diagnostikovanou vysoce rizikovou akutní promyelocytární leukémií.

E.2.2

Secondary objectives of the trial

• To evaluate the short- and long-term toxicity profile of ATO in pediatric patients, when combined with ATRA (SR APL) or ATRA plus GO (HR APL)
• To compare the clearance kinetics of minimal residual disease (MRD) with that of the previous AIDA-like protocols, COG protocol and ICC APL Study 01
• To estimate the cumulative incidence of both molecular and hematological relapse
• To calculate the probability of overall survival and the early death rate
• To prospectively evaluate the impact of FLT3-ITD on this patient population
• To compare the duration of hospitalization and quality of life with those of the previous AIDA-like protocols and ICC APL study 01

Účelem výzkumu, který je zde prezentován, je dosáhnout následujících sekundárních cílů:
• zhodnotit krátkodobý a dlouhodobý profil toxicity ATO v kombinaci s ATRA u pacientů se standardně rizikovou akutní promyelocytární leukémií;
• porovnat vývoj minimální zbytkové nemoci s předchozími léčebnými protokoly;
• odhadnout výskyt molekulární a hematologické recidivy (tzn. návratu onemocnění);
• vypočítat pravděpodobnost celkového přežití a míru předčasné úmrtnosti;
• porovnat délku hospitalizace a kvalitu života s předchozími léčebnými protokoly.
• zhodnotit krátkodobý a dlouhodobý profil toxicity ATO v kombinaci s ATRA a GO u dětských pacientů s vysoce rizikovou akutní promyelocytární leukémií;

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

- Newly diagnosed APL confirmed by the presence of PML/RARα fusion gene
- Age <18 years
- Written informed consent by parents or legal guardians
- WBC at diagnosis ≥10 x 109/L
- If applicable, female participants must have pregnancy test by beta-HCG dosing and be negative.
- Patients of child-bearing or child-fathering potential must be willing to practice and must contact their physician. With their physician, they must agree on the most appropriate approach for birth control from the time of enrollment in this study and for 3 months after receiving the latest infusion.

- nově diagnostikovaná APL potvrzená přítomností fúzního genu PML/RARα
- věk <18 let
- podepsaný informovaný souhlas rodiči/zákonným zástupcem
- u dívek ve fertilním věku negativní těhotenský test

E.4

Principal exclusion criteria

Patients with a clinical diagnosis of APL but subsequently found to lack PML/RARα rearrangement should be withdrawn from the study and treated with an alternative protocol
- Significant liver dysfunction (bilirubin serum levels >3 mg/dL, ALT/AST serum levels greater than 5 times the normal values)
- Creatinine serum levels >2 times the normal value for age
- Significant arrhythmias, EKG abnormalities (*see below), other cardiac contraindications (L-FEV < 50% or LV-FS <28%)
- Neuropathy grade 2 or greater
- Concurrent active malignancy
- Uncontrolled life-threatening infections
- Pregnant or lactating females
- Patients who had received alternative therapy (APL not initially suspected; ATRA and/or ATO not available)

- pacienti s klinickou diagnózou APL bez přítomnosti fúzního genu PML/RARα
- významná jaterní dysfunkce (hladina bilirubinu>3 mg/dL, hladina ALT/AST>5-násobek horního limitu normy)
- kreatinin >2-násobek horního limitu věkově příslušné normy
- významné arytmie, EKG abnormality (viz*), jiné kardiální kontraindikace (L-FEV < 50% nebo LV-FS <28%)
- neuropatie grade 2 nebo vyšší
- souběžná aktivní malignita
- nekontrolovaná život ohrožující infekce
- těhotenství nebo kojení
- sexuálně aktivní adolescenti, kteří odmítají používání vysoce efektivních antikoncepčních metod po celou léčbu a minimálně 3 měsíců po skončení protileukemické léčby
- pacienti, kteří vstupně dostali jinou terapii APL

E.5 End points

E.5.1

Primary end point(s)

• The primary endpoint of the study is event-free survival (EFS). This cumulative endpoint includes the following events: no achievement of hematological complete remission after induction therapy; no achievement of molecular remission after three consolidation courses (molecular resistance); relapse (hematological/molecular); death, including early death, at 2 years from diagnosis. We aim at reaching a 3-year EFS probability of 90% (95% CI: 84.1-95.9%) and 80% (95% CI: 72.1-87.9%) in SR and HR patients, respectively.

SR-ICC APL 02 pro pacienty standardního rizika
Přežití bez události (event-free survival) při léčbě kombinací oxidu arsenitého (ATO) a all-trans retinové kyseliny (ATRA) u nově diagnostikované APL standardního rizika u dětí a adolescentů.

HR-ICC APL 02 pro pacienty vysokého rizika
Přežití bez události (event-free survival) při léčbě kombinací gemtuzumab ozogamicinu (GO), oxidu arsenitého (ATO) a all-transretinové kyseliny (ATRA) u nově diagnostikované APL vysokého rizika u dětí a adolescentů

E.5.1.1

Timepoint(s) of evaluation of this end point

2 years

2 roky

E.5.2

Secondary end point(s)

• Rate of hematological CR after induction
• Rate of early and aplastic death during induction
• Overall survival (OS)
• Cumulative incidence of either hematological and molecular relapse (CIR)
• Incidence of hematological and non-hematological toxicity
• Kinetics of MRD clearance
• Rate of molecular remission after 3 consolidation cycles
• Assessment of PML/RARα transcript level reduction during treatment
• Toxicity - hematological and non-hematological
• Supportive care requirements
• Total hospitalization days during therapy and health economic impact

SR-ICC APL 02 pro pacienty standardního rizika
Krátkodobý a dlouhodobý profil toxicity ATO v kombinaci s ATRA u pediatrických pacientů.
Srovnání kinetiky minimální reziduální nemoci (MRN) s předchozími protokoly AIDA, COG a ICC APL01.
Kumulativní incidence molekulárních a hematologických relapsů.
Pravděpodobnost celkového přežití a časných úmrtí.
Vliv přítomnosti FLT3-ITD v pacientské populaci.
Srovnání délky hospitalizace a kvality života s předchozími protokoly AIDA, COG a ICC APL01.

HR-ICC APL 02 pro pacienty vysokého rizika
Krátkodobý a dlouhodobý profil toxicity kombinace GO, ATO a ATRA u pediatrických pacientů
Srovnání kinetiky minimální reziduální nemoci (MRN) s předchozími protokoly AIDA, COG a ICC APL01
Kumulativní incidence molekulárních a hematologických relapsů
Pravděpodobnost celkového přežití a časných úmrtí
Vliv přítomnosti FLT3-ITD v pacientské populaci
Srovnání délky hospitalizace a kvality života s předchozími protokoly AIDA, COG a ICC APL01

E.5.2.1

Timepoint(s) of evaluation of this end point

2 years

2 roky

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

Yes

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

E.6.7

Pharmacodynamic

E.6.8

Bioequivalence

E.6.9

Dose response

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

Yes

E.7.3

Therapeutic confirmatory (Phase III)

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

E.8.1.1

Randomised

E.8.1.2

Open

E.8.1.3

Single blind

E.8.1.4

Double blind

E.8.1.5

Parallel group

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

E.8.2.2

Placebo

E.8.2.3

Other

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.7

Trial has a data monitoring committee

Yes

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LVLS

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

E.8.9.2

In all countries concerned by the trial days

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

Yes

F.1.1